This page contains brief information about ciltacabtagene autoleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ciltacabtagene autoleucel is approved to treat:
- Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent.
Ciltacabtagene autoleucel is only available as part of a special program called Carvykti REMS (Risk Evaluation and Mitigation Strategies).
More About Ciltacabtagene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Ciltacabtagene Autoleucel - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma
FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma
NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials
CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
Clinical Trials Accepting Patients
Find Clinical Trials for Ciltacabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.